Destiny-Breast 09 Case Study

SABCS 2022: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 + Q & A

Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

GS3-02. Updated overall survival (OS) results from the phase 3 PHOEBE trial

Dr Bardia on Current Approaches to HER2+ Breast Cancer Management

Breast Cancer Breakthroughs: Issues and upcoming research for advanced HER2-positive breast cancer

Destiny-Breast 03 Case Study

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast Cancer

Breast cancer research at ESMO 2021

Education Session HER2+ Breast Cancer Updates from the Clinic and the Lab

Selecting and Sequencing of HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer

Dr. Shanu Modi | San Antonio Breast Cancer Symposium 2022 | Educational Session

A Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2+ Breast Cancer

Breast Cancer Breakthroughs Episode 5: Moving the Needle for HER2-positive Breast Cancer

Research Update for HER2-Positive MBC | 2022-2023 EMBRACE MBC Virtual Forum Series

HER2Podcast

Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metas...

Oncology Today with Dr Neil Love — HER2-Positive Metastatic Breast Cancer

Medical update: HER2-Positive and triple-positive metastatic breast cancer